Tirzepatide
Supplied by U.S. pharmacies.
Description
Formulation Facts
- Reference labeling describes tirzepatide as a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.[1]
- The supplied records differ on whether pyridoxine is named in the injection listing.
The supplied tracker identifies tirzepatide as an injection.[1]
Active Ingredient Identity and Pharmacy Records
Reference drug labels classify tirzepatide as a dual GIP and GLP-1 receptor agonist.[1] Current pharmacy entries document an injectable medication, yet available records do not establish the complete recipe or confirm whether pyridoxine is present in dispensed vials.
Frequently Asked Questions
Is tirzepatide a combination of two separate peptides?
Tirzepatide is a single active molecule that binds to both GIP and GLP-1 receptors.[1] Tirzepatide itself is not a mixture of two peptide ingredients.
Does the pharmacy listing include pyridoxine?
The tracker example names tirzepatide with pyridoxine, while the pharmacy catalog row names tirzepatide injection without specifying pyridoxine. The available documentation does not resolve whether the dispensed compound contains pyridoxine as an added ingredient.
Information Sources
Compounding and Regulatory Considerations
Compounded drugs are not approved by the U.S. Food and Drug Administration (FDA).[2] The FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.[2]
Personalized Clinical Consultations
Opt Health offers video consultations with licensed physicians who review blood test results, current medications and individual health goals.[3][4]
Learn How Opt Health WorksThis content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.